Connect with us

Healthcare

Ind-swift Laboratories Limited (indswftlab) to Make Jammu Facility EUGMP and PICS Compliant

Ind-Swift Laboratories Limited (INDSWFTLAB) to upgrade Jammu facility to EUGMP and PICS standards, targeting additional revenue of ₹100 crores from 2029-30.

Deputy Editor, Equities for tradealone

Published

on

Ind-swift Laboratories Limited Indswftlab Q1 FY27 Compliance

Ind-Swift Laboratories Limited (INDSWFTLAB) is upgrading its manufacturing facility in Jammu, J&K to meet EU-GMP and PICS standards. This move aims to meet the increased demand for its products in the export market. The facility, which currently caters to the domestic market and soft regulated markets, is expected to generate additional revenues of ₹100 crores from the European and other regulated markets from FY 2029-30. The plant is anticipated to be compliant and approved by early 2028. The total investment for the plant upgradation is around ₹45 crores, excluding investments in R&D for facility upgradation, product development, and production registrations.

Facility Expansion

The Jammu facility, built in 2008 and covering 14,700 sq meters, has an installed capacity to manufacture Oral Solid Dosage (OSD) and Ointments. Post-upgradation, the facility will cater to markets across the world, supplementing both the CDMO and own branding business of the company.

Financial Performance

The company recently declared its Q1 financial results for FY27. Operating income grew 21.16% year-on-year to ₹186.08 crore, from ₹153.58 crore in Q1 FY26. Operating EBITDA improved 2.85 times year-on-year to ₹33.32 crore, from ₹8.66 crore in the corresponding quarter last year. Moreover, operating EBITDA margin expanded sharply by 1,258 basis points year-on-year to 17.91%, from 5.33% in Q1 FY26. PAT, excluding exceptional items, stood at ₹24.68 crore, a 2.04 times year-on-year jump from ₹8.12 crore. PAT margin improved by 827 basis points year-on-year to 13.26%, from 4.99% in the corresponding quarter of the previous year.

As a result, the company is well-positioned to leverage its upgraded facility to tap into new revenue streams and enhance its market presence globally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

INDSWFTLAB
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
40
Fundamental
68
Technical
54
Overall

1W -7.28%
1M -4.31%
3M +7.58%
P/E: 34.9 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Ind-Swift gains 106.1% over three months and trades near its 52-week highs. Thin margins at 6.5% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -19.0% CAGR. That signals structural headwinds, not a short-term blip. RSI hits 78, a level that signals the stock runs hot. Notably, buyers drove volume on 18 recent sessions — though at these levels, some profit-taking is normal. The stock rises 106.1% in three months. Yet revenue grows at only -19.0% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Ind-Swift Laboratories Limited.

BIOCON

Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU

Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.

abhinav tiwari

Published

on

Biocon Limited Biocon November 2026 Event

Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.

First Biosimilar Under New Clinical Approach

Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”

Broadening Treatment Options

The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.

As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
APPROACHING RESISTANCE
52
Fundamental
56
Technical
54
Overall

1W -1.66%
1M +6.46%
3M -12.15%
P/E: 121.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

GLENMARK

Glenmark Pharmaceuticals Limited (glenmark) Announces IND Submission for ISB 2301

Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.

Pranab Tyagi at TradeAlone

Published

on

Glenmark Pharmaceuticals Limited Glenmark IND Submission

Glenmark Pharmaceuticals Limited (GLENMARK) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301. The focus keyword, Glenmark Pharmaceuticals Limited GLENMARK IND Submission, highlights this significant milestone in the company’s oncology pipeline. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and natural killer (NK) cells.

Advancement in Multispecific Oncology Pipeline

The IND submission marks an important step in advancing Ichnos Glenmark Innovation’s (IGI) multispecific oncology pipeline into clinical development. ISB 2301, engineered using IGI’s proprietary BEAT® Multispecific Platform, combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. This pentaspecific molecule is designed to address biological heterogeneity and immune-suppressive features of solid tumors.

Planned Phase 1 Clinical Trial

IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027. Preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, showing favorable pharmacokinetic and tolerability profiles in non-human primates. The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of ISB 2301 in patients with advanced solid tumors.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GLENMARK
Healthcare › Drug Manufacturers - Specialty & Generic
BREAKOUT
78
Fundamental
94
Technical
86
Overall

1W -1.16%
1M +19.72%
3M +13.62%
P/E: 51.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Glenmark rises 12.3% over three months, with buying pressure holding steady. The PEG of 0.77 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 9.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.77 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Continue Reading

Drug Manufacturers - General

Sai Parenterals Limited (saiparent) Acquires Majority Stake in Bion Therapeutics’ Prescription Business

Sai Parenterals Limited (SAIPARENT) announces acquisition of Bion Therapeutics’ prescription business, adding 16 brands and enhancing market presence.

Pranab Tyagi at TradeAlone

Published

on

Sai Parenterals Limited Saiparent November 2026 Acquisition

Sai Parenterals Limited (NSE: SAIPARENT) has announced a strategic move to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. This acquisition, executed through its wholly owned subsidiary SP Analytics Private Limited, is expected to be finalized before the end of this month. The transaction will be an all-cash deal, significantly strengthening Sai Parenterals’ presence in India’s prescription market.

Strategic Benefits

The acquisition of Bion Therapeutics will add 16 established brands and around 250 field staff to Sai Parenterals, enhancing its competitive position in the domestic pharmaceutical landscape. Bion’s extensive infrastructure provides immediate access to a broader market, integrating with Sai Parenterals’ manufacturing capabilities to ensure assured supply, consistent quality, and improved margins.

Operational Integration

Bion’s portfolio, currently manufactured by third parties, will progressively transfer to Sai Parenterals’ accredited facilities, which hold TGA-Australia and WHO-GMP accreditations. This move will allow Bion’s brands to leverage Sai Parenterals’ development pipeline and Noumed’s dossier library, offering a wider portfolio to its existing doctor coverage. The critical-care injectable facility, SAICRITI, due for completion in August 2027, will provide a route into hospital and critical-care segments for Bion’s injectable brands.

Forward-Looking Vision

Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, emphasized the strategic importance of this acquisition in converting development capability into branded revenue. The value flows in both directions, with Bion’s portfolio transferring to Sai Parenterals’ facilities and Sai Parenterals’ development pipeline broadening Bion’s market offerings. Further particulars of the transaction will be disclosed at the appropriate stage.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SAIPARENT
Healthcare › Drug Manufacturers - General
CONSOLIDATING DOWN
72
Fundamental
66
Technical
70
Overall

1W -0.83%
1M +3.88%
3M -9.1%
P/E: 89 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Sai falls 8.2% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 57.9% and profits at 48.3% CAGR. Both numbers are exceptional. The stock gains 3.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 57.9% and profits at 48.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 8.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.

Continue Reading

Trending